ALXO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ALX Oncology Holdings Inc. (ALXO) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's financial performance is weak, with declining net income and EPS. While the technical indicators show some bullish trends, the lack of significant positive catalysts, weak trading sentiment, and no recent signals from Intellectia Proprietary Trading Signals suggest that waiting for better opportunities would be prudent.
The MACD is positive and contracting, indicating a potential slowdown in bullish momentum. RSI is neutral at 73.979, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 2.501 and 2.735, with support at 1.745 and 1.511.
The stock has a 60% chance of a 9.37% increase in the next month based on historical candlestick patterns. Analysts at Piper Sandler raised the price target from $3 to $4, maintaining an Overweight rating.
No significant hedge fund or insider trading activity. No recent news or congress trading data. The company reported declining financial performance, with a YoY drop in net income (-27.89%) and EPS (-29.31%).
In Q3 2025, the company reported no revenue growth (0% YoY), a net income drop of -27.89% YoY, and an EPS decline of -29.31% YoY. Gross margin remained at 0%.
Piper Sandler raised the price target to $4 from $3 and maintained an Overweight rating, reflecting optimism about the company's breast cancer pipeline.
